Provided herein are antibodies and antigen binding fragments thereof specific to BCG antigen Ag85B as well as chimeric antigen receptors and lymphocytes comprising Ag85B antibodies as described and methods of treating cancer and tuberculosis infections using the CAR lymphocytes described. In a first aspect, provided herein is an isolated antibody or antigen binding fragment thereof capable of binding Bacillus Calmette-Guerin (BCG) antigen Ag85B.

Provided herein are antibodies and antigen binding fragments thereof specific to BCG antigen Ag85B as well as chimeric antigen receptors and lymphocytes comprising Ag85B antibodies as described and methods of treating cancer and tuberculosis infections using the CAR lymphocytes described. In a first aspect, provided herein is an isolated antibody or antigen binding fragment thereof capable of binding Bacillus Calmette-Guerin (BCG) antigen Ag85B.

An aluminum nanoparticle adjuvant carrier system with stabilizing surface coatings that can efficiently deliver protein or nucleic acid antigen payloads to naive, resident APCs is disclosed.

An aluminum nanoparticle adjuvant carrier system with stabilizing surface coatings that can efficiently deliver protein or nucleic acid antigen payloads to naive, resident APCs is disclosed.

Disclosed is the use of foam compositions for the delivery of therapeutics to a body cavity, organ, or tissue of a patient in need thereof. Also disclosed are foam compositions, and devices for delivering the composition to a body cavity or the interior or exterior of an organ. Additionally, methods of treating cancer in the internal organs or the body cavity using the foam compositions are also disclosed.

Disclosed is the use of foam compositions for the delivery of therapeutics to a body cavity, organ, or tissue of a patient in need thereof. Also disclosed are foam compositions, and devices for delivering the composition to a body cavity or the interior or exterior of an organ. Additionally, methods of treating cancer in the internal organs or the body cavity using the foam compositions are also disclosed.

The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.

Fusion proteins, recombinant Bacillus cereus family members that express fusion proteins, and exosporium fragments derived from spores of the recombinant Bacillus cereus family members are provided. Compositions comprising the spores or exosporium fragments are also provided. Methods involving the use of spores of recombinant Bacillus cereus family members and exosporium fragments derived from spores of a recombinant Bacillus cereus family member in the fields of animal health and aquaculture are provided. In particular, methods are for provided for using such spores or exosporium fragments for protecting an animal or an aquatic organism from a pathogen. Methods are also provided for using exosporium fragments for producing an immunogenic response in an aquatic animal. Products for use in protecting animals from pathogens are also provided, including adhesive patches, wound dressings, insert trays for livestock footbaths, hoof bandages, feed, feed additives, and insect foggers.

Various embodiments of the present invention are directed to the field of Oncology, and in particular, embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. Certain embodiments are directed to the field of human longevity and aging in a manner such that cancer is not contracted due to ameliorating, treating, or reducing aging by increasing the healthspan and lifespan of humans. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, rapamycin, p53 protein, statins, etc., is employed to treat and prevent cancer and other age-related diseases.

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.